Overview

A Study Demonstrating The Effect Of Latanoprost In Combination With Timolol, Latanoprost Alone And Timolol Alone On Eye Pressure In Open Angle Glaucoma Or Ocular Hypertension In Patients

Status:
Completed

Trial end date:
1999-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to demonstrate that fixed combination of latanoprost and timolol (PhXA41) has better IOP lowering effect than the individual monotherapies.

Phase:

Phase 3

Details

Lead Sponsor:

Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatments:

Latanoprost
Ophthalmic Solutions
Pharmaceutical Solutions
Timolol